GLP-1 medications differ in three ways that matter: how many receptors they act on, how they are taken, and what evidence sits behind them. Semaglutide targets the GLP-1 receptor alone. Tirzepatide adds a second target, the GIP receptor. Orforglipron is a once-daily oral pill rather than an injection. Those distinctions change effect size, side effects, dosing routine, and who a given drug suits, so treating the whole group as interchangeable is a mistake.
What does the GLP-1 receptor actually do?
Glucagon-like peptide-1 is a hormone released after eating. Drugs in this class mimic it, which slows stomach emptying, prompts insulin release when glucose is high, and reduces appetite through signaling in the brain. A 2024 review of the mechanisms behind these drugs describes how that combination lowers blood sugar and body weight, and why the effects on hunger are as important as the effects on glucose. That shared biology is the reason people group these drugs together. It is also why the group is easy to oversimplify.
The differences begin once a second receptor enters the picture. GIP, another gut hormone, has its own effects on insulin and fat metabolism. Adding activity at that receptor is the basis for the dual agonists, and it is where the class stops being one thing.
Single receptor or dual receptor: does it change results?
Semaglutide is a single-receptor GLP-1 agonist. Tirzepatide acts on both GIP and GLP-1 receptors, a design first described in a 2018 report on the molecule then called LY3298176, which traced its path from discovery through early proof-of-concept work in type 2 diabetes. In practice the dual agonist tended to produce larger reductions in weight and blood sugar in its own trials.
That is not the same as a head-to-head win, and it should not be read that way. The trials were run separately, in different populations, at different times. What can be said fairly is that adding GIP activity appears to increase effect for many people, while also carrying its own gastrointestinal side-effect profile. More effect is not automatically the right goal for a given patient.
See also: Technology for Renewable Energy
How do the delivery routes compare?
| Type | Receptor target | Route | Approval status |
|---|---|---|---|
| Semaglutide (peptide) | GLP-1 | Weekly injection or daily oral peptide | FDA-approved |
| Tirzepatide (peptide) | GIP and GLP-1 | Weekly injection | FDA-approved |
| Orforglipron (small molecule) | GLP-1 | Once-daily oral tablet | FDA-approved (FOUNDAYO, 2026) |
| Retatrutide | GIP, GLP-1, glucagon | Injection | Investigational |
| Compounded semaglutide or tirzepatide | Same molecule as brand | Injection | Not FDA-approved |
Why is orforglipron a genuine departure?
Almost every GLP-1 drug before it was a peptide, which is why they were injected or, in one oral form, taken under strict fasting rules. Orforglipron is a small molecule, meaning it can be made as an ordinary daily tablet. Early trial work published in 2023 showed the oral agonist produced meaningful weight reduction in adults with obesity, and a later phase 3 report in 2025 backed that up in a larger group. The FDA approved it as FOUNDAYO in 2026 for weight management, and a 2026 first-approval summary records that milestone.
For anyone who has avoided this class because of needles or peptide dosing rules, that matters. A daily pill is a different commitment from a weekly injection, and it may widen who is willing to start treatment at all. Orforglipron is not investigational; it is an approved option, and it belongs on the list of real choices rather than the pipeline.
What does the guidance say about picking among them?
Clinical guidelines have moved toward treating obesity as a chronic condition with drug therapy as a legitimate tool, not a last resort. The 2025 clinical practice guideline update on pharmacotherapy for obesity, the AGA guideline on pharmacological interventions, and a 2025 statement redefining clinical obesity all point the same direction: match the drug to the person and the diagnosis. GLP-1 agonists also appear in the EASL-EASD-EASO guidance on metabolic dysfunction-associated steatotic liver disease, which shows the class reaching beyond weight and glucose into related metabolic disease.
The practical read is that no single GLP-1 medication is the answer for everyone. A drug that suits someone with type 2 diabetes and liver disease may not be the first pick for someone whose main issue is weight and who cannot tolerate strong gastrointestinal effects.
Where do compounded versions fit?
Compounded semaglutide and tirzepatide are prepared by compounding pharmacies rather than made under an approved application. They are not FDA-approved products, and they have not been through the process that generated the trial evidence discussed above. That distinction is real. What they often provide is a flat monthly cash price for people without coverage.
Direct-to-consumer names in this space vary in how they operate. Ro, Hims and Hers, Henry Meds, LillyDirect, and NovoCare each take a different route, some routing to brand medication and some to compounded. Physician-supervised telehealth practices such as the one described at formblends.com publish flat pricing and handle prescribing through a licensed clinician, which is one legitimate option among that field rather than a substitute for the approval evidence behind the brands. The trade is regulatory assurance for cost predictability, and whether that trade is reasonable belongs with a prescriber who knows the case.
Key takeaways
- These drugs share a receptor family but differ in target count, dosing route, and evidence.
- Tirzepatide adds GIP activity and showed large effects in its own trials, which is not a head-to-head result.
- Orforglipron is an approved once-daily oral option, not an investigational one.
- Retatrutide remains investigational, and compounded versions are not FDA-approved products.
- The right choice depends on diagnosis, tolerance, and access, so it is a prescriber decision.
Frequently asked questions
Are all GLP-1 medications basically the same drug?
No. They share a receptor target but differ in whether they hit one receptor or two, how they are dosed, and what trials support them. Semaglutide acts on the GLP-1 receptor alone, tirzepatide acts on both GIP and GLP-1, and orforglipron is a daily oral small molecule rather than an injection.
Is a dual receptor drug automatically better?
Not automatically. Tirzepatide adds GIP receptor activity and produced large weight reductions in its trials, but the right choice depends on the condition being treated, tolerability, and access, not on receptor count alone.
How is orforglipron different from the injectables?
It is a once-daily oral small-molecule GLP-1 receptor agonist, not a peptide injection. FOUNDAYO was approved by the FDA in 2026 for weight management, which makes it the first oral option in this class taken as a simple daily pill without food and water restrictions unique to earlier oral peptides.
Is compounded GLP-1 medication the same as the brand?
No. A compounded version is prepared by a compounding pharmacy and is not an FDA-approved product. It may contain the same active molecule, but it has not been through the approval process that generated the published trial evidence.
Which GLP-1 medication should someone choose?
That depends on the diagnosis, other conditions, tolerance, dosing preference, and coverage. The differences between these drugs are real, so the decision belongs with a prescriber who knows the full picture rather than a ranking chart.
